Pure Global
NCT05178017

Lifestyle Eating and Performance (LEAP) Program for the Treatment of Irritable Bowel Syndrome (IBS)

Effectiveness of the Lifestyle Eating and Performance (LEAP) Program for the Treatment of Irritable Bowel Syndrome (IBS)
Oxford Biomedical Technologies, Inc.·ClinicalTrials.gov·diagnostic testRecruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
IBS - Irritable Bowel Syndrome
Drug/Device/Intervention
Leukocyte Activation Assay (LAA-MRT) / Lifestyle Eating and Performance (LEAP) program
Study type
Interventional
Intervention type
diagnostic test
Sponsor & location
Primary sponsor
Oxford Biomedical Technologies, Inc.
Location
Riviera Beach, United States of America
Timeline & enrollment
Phase
N/A
Start date
Sep 01, 2021
End date
Dec 01, 2023
Enrollment
60 participants
Primary outcome

Inflammatory blood markers

Summary

A three month follow-up study to evaluate the effectiveness of a tailored anti-inflammatory
 eating plan guided by a registered dietitian to treat irritable bowel syndrome.

ICD-10 classifications
Irritable bowel syndrome with predominant constipation [IBS-C]Irritable bowel syndromeIrritable bowel syndrome with predominant diarrhoea [IBS-D]Irritable bowel syndrome with mixed bowel habits [IBS-M]Other and unspecified irritable bowel syndrome
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT05178017
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT05178017 through Pure Global AI's free database. This phase not specified trial is sponsored by Oxford Biomedical Technologies, Inc. and is currently Recruiting. The study focuses on IBS - Irritable Bowel Syndrome. Target enrollment is 60 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.